Clincosm LogoSign in Get a demo

Gastric Neuromuscular Function in GERD

Sponsor
The Functional Gut Clinic (Other)
Overall Status
Recruiting
CT.gov ID
NCT05719168
Collaborator
(none)
60
Enrollment
1
Location
2
Arms
14
Anticipated Duration (Months)
4.3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Bodysurface gastric mapping (BSGM) will be used to assess gastric neuromuscular function in healthy controls and patients with medical refractory gastroesophageal reflux disease (GERD).

Participants will undergo BSGM for 4-hours in addition to high resolution manometry (HRM), pH-impedance monitoring, and gastric emptying breath test.

Condition or Disease Intervention/Treatment Phase
  • Device: Body Surface Gastric Mapping
 N/A

Detailed Description

This is a clinical trial of a non-invasive BSGM medical device (Gastric Alimetry) in patients with medical refractory GORD and healthy controls to determine the differences in gastric electrical activity, and correlate with adjacent measurements of gastro-esophageal function.

Patients referred to the Functional Gut Clinic for standard care investigation of GORD with HRM and pH-impedance monitoring will be recruited. Healthy volunteers will be recruited via advertisement.

All patients and healthy volunteers will undergo BSGM at the research site, which lasts around 4.5 hours. After a 0.5 hour baseline, subjects will undergo HRM and pH-impedance monitoring concomitantly. A test meal of porridge with C13 labelled octanoic acid will be consumed with BSGM and breath samples recorded for 4.0 hours after meal completion. The HRM catheter will be removed after 1.0 hour from finishing the test meal whist the pH-impedance monitoring will continue for the remainder of the site visit and for the remainder of the 24-hour study period whilst the subject is at home to quantify reflux.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Prospective, cross-sectionalProspective, cross-sectional
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Exploring the Role of Gastric Neuromuscular Function in the Pathophysiology of Proton Pump Inhibitor (PPI) Refractory Gastresophageal Reflux Disease (GERD)
Actual Study Start Date :
Oct 1, 2022
Anticipated Primary Completion Date :
Oct 1, 2023
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Patients with medical refractory GERD

Participants undergo BSGM for 4.5 hours with simultaneous oesophageal manometry, pH-impedance monitoring and gastric emptying breath tests. Following completion, participants continue with ambulatory pH-impedance monitoring for a further 24-hours. Participants undergo a hydrogen and emthane breath test on a seperate day.

Device: Body Surface Gastric Mapping
64-channel electrode array placed on the outer abdomen
Active Comparator: Healthy controls without gastrointestinal symptoms

Participants undergo BSGM for 4.5 hours with simultaneous oesophageal manometry, pH-impedance monitoring and gastric emptying breath tests. Following completion, participants continue with ambulatory pH-impedance monitoring for a further 24-hours.

Device: Body Surface Gastric Mapping
64-channel electrode array placed on the outer abdomen

Outcome Measures

Primary Outcome Measures

  1. Difference in BSGM parameters between GORD and healthy controls [24-hours]

    Gastric Alimetry Rhythm Index (Normal >0.25)

  2. Difference in BSGM parameters between GORD and healthy controls [24-hours]

    Prinicpal Gastric Frequency (Normal: 2.65-3.35cpm)

  3. Difference in BSGM parameters between GORD and healthy controls [24-hours]

    Fed:Fasted Amplitude ratio (Normal: >1.08)

  4. Difference in BSGM parameters between GORD and healthy controls [24-hours]

    Average Amplitude (Normal: 20-70 microvolts)

  5. Difference in BSGM parameters between GORD and healthy controls [24-hours]

    % of retrograde activity

Secondary Outcome Measures

  1. Normal reference ranges for gastric emptying and BSGM [24-hours]

    T lag and T 1/2 time (minutes)

  2. Correlate reflux event frequency with Gastric Alimetry Rhythm Index [24-hours]

    Frequency of reflux events with Gastric Alimetry Rhythm Index

  3. Correlate reflux event frequency with Prinicpal Gastric Frequency (cpm) [24-hours]

    Frequency of reflux events with Prinicpal Gastric Frequency (cpm)

  4. Correlate reflux event frequency with Fed:Fasted Amplitude ratio [24-hours]

    Frequency of reflux events with Fed:Fasted Amplitude ratio

  5. Correlate reflux event frequency with Average Amplitude [24-hours]

    Frequency of reflux events with Average Amplitude (microvolts)

  6. Correlate reflux event frequency with % of retrograde activity [24-hours]

    Frequency of reflux events with % of retrograde activity

  7. Correlate symptom severity with BSGM parameters [24-hours]

    Real time discrete (vomiting, belching, reflux counts) and continuous (Nausea, bloating, upper gut pain, heartburn, stomach burn and excessive fullness) gastrointestinal symptom scores at both pre- and post-prandial time periods determined by a series of multiple 10-point symptom severity scales integrated within the validated Gastric Alimetry iOS Application with Gastric Alimetry Rhythm Index

  8. Correlate quality of life with BSGM parameters [24-hours]

    Total symptom burden scores according to the PAGI-QOL with Gastric Alimetry Rhythm Index

  9. Correlate the results of gastric emptying with BSGM parameters [24-hours]

    T lag and T 1/2 (minutes) with ith Gastric Alimetry Rhythm Index

  10. Correlate the results of oesophageal manometry with BSGM parameters [24-hours]

    Distal contractile integral (mmHg.s.cm) with Gastric Alimetry Rhythm Index

  11. Correlate the results of oesophageal manometry with Gastric Alimetry Rhythm Index [24-hours]

    Integrated relaxation pressure (mmHg) with Gastric Alimetry Rhythm Index

  12. Correlate the results of oesophageal manometry with Prinicpal Gastric Frequency [24-hours]

    Integrated relaxation pressure (mmHg) with Prinicpal Gastric Frequency

  13. Correlate the results of oesophageal manometry with Prinicpal Gastric Frequency [24-hours]

    Integrated relaxation pressure (mmHg) with % of retrograde activity

  14. Correlate the results of oesophageal manometry with Gastric Alimetry Rhythm Index [24-hours]

    Frequency of transient lower oesophageal sphincter relaxation (TLOSRs) with Gastric Alimetry Rhythm Index

  15. Correlate the results of oesophageal manometry with Gastric Alimetry Rhythm Index [24-hours]

    Frequency of transient lower oesophageal sphincter relaxation (TLOSRs) with Prinicpal Gastric Frequency

  16. Correlate the results of oesophageal manometry with % of retrograde activity [24-hours]

    Frequency of transient lower oesophageal sphincter relaxation (TLOSRs) with % of retrograde activity

  17. Correlate the results of hydrogen and methane breath testing with Gastric Alimetry Rhythm Index [7 days]

    Total gas production (AUC ppm) with Gastric Alimetry Rhythm Index

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes

Healthy controls

Inclusion Criteria:

  • Aged 18-70 years old

  • BMI 18-35

  • Able to understand written and spoken English

  • Able to provide written consent

  • Able to understand risks and benefits

Exclusion Criteria:

  • Antacid use (e.g. PPI, H2RA or Gaviscon) within last 12-months

  • Active use of other medications known to impact gastric motility

  • Upper GI symptoms including but not limited to heartburn, regurgitation, epigastric pain, nausea and bloating

  • Significant medical condition

  • History of skin allergies or hypersensitivity

  • Active abdominal wounds or abrasions, fragile skin

  • Current pregnancy

  • Vulnerable group e.g. prisoners/cognitive impairment/institutionalised individuals

  • Regular cannabis users (unable to abstain for 7-days)

  • Opioid user

  • Unable to use a tablet device

GORD patients

Inclusion Criteria

  • Referred for 24-hour pH-impedance monitoring

  • Aged 18-70 years old

  • BMI 18-35

  • Able to understand written and spoken English

  • Able to provide written consent

  • Able to understand risks and benefits

Exclusion Criteria

  • Systemic or metabolic disorder known to cause gastric dysmotility other than diabetes (e.g. scleroderma, multiple sclerosis, hyperthyroidism).

  • History of upper GI surgery or hiatal hernia (>5cm, paraesophageal, or 'large' on endoscopy report)

  • Diabetic and on insulin

  • Proven mechanical bowel obstruction

  • History of skin allergies or hypersensitivity

  • Active abdominal wounds or abrasions, fragile skin

  • Current pregnancy

  • Vulnerable group - prisoners/cognitive impairment/institutionalised individuals

  • Regular cannabis users (unable to abstain for 7-days)

  • Opioid user

  • Unable to use a tablet device

Contacts and Locations

Locations

Site City State Country Postal Code
1 The Functional Gut Clinic Manchester Greater Manchester United Kingdom M3 4BG

Sponsors and Collaborators

  • The Functional Gut Clinic

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Dr Anthony Hobson, Clinical Director, The Functional Gut Clinic
ClinicalTrials.gov Identifier:
NCT05719168
Other Study ID Numbers:
  • FGC-22-002
First Posted:
Feb 8, 2023
Last Update Posted:
Feb 8, 2023
Last Verified:
Jan 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:
Gastroesophageal Reflux

Study Results

No Results Posted as of Feb 8, 2023